Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-4

Highlights and conclusions

• Intratumoral (IT) treatment with CF33-hNIS-anti-PD-L1 is safe and well-tolerated
at dose levels 1 through 3.
IMUGENE LIMITED ACN 009 179 551 3

• CF33-hNIS-anti-PD-L1 IT injection induces tumor infiltration of CD4+ and CD8+ Tcells which are critical immune cells signalling localised immune activation
connected to CF33-hNIS-anti-PD-L1 injection.

• Significant upregulation of PD-L1 within the tumor microenvironment (TME) further
suggests immune activation by CF33-hNIS-anti-PD-L1, an important precursor for
immune clearance of tumors.

• SPECT imaging after treatment with CF33-hNIS-anti-PD-L1 showed enhancement
at injected lesions in 75% of patients, suggesting local viral replication and hNIS
expression. This shows successful tracking of viral replication using non-invasive
imaging studies.

Is it time to insert the rocket emojis? Please lord have mercy on our SP and let this be the bottom and the start of a new upward trajectory! GLTAH